

Qing Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3632416/publications.pdf>

Version: 2024-02-01

173
papers

5,816
citations

109321

35
h-index

102487

66
g-index

179
all docs

179
docs citations

179
times ranked

8843
citing authors

#	ARTICLE	IF	CITATIONS
1	Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. <i>BMJ, The</i> , 2020, 369, m1849.	6.0	811
2	Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. <i>Gastroenterology</i> , 2019, 156, 2230-2241.e11.	1.3	346
3	CSH guidelines for the diagnosis and treatment of drug-induced liver injury. <i>Hepatology International</i> , 2017, 11, 221-241.	4.2	206
4	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. <i>Hepatology</i> , 2013, 58, 872-880.	7.3	201
5	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	3.7	158
6	Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.. <i>Scientific Reports</i> , 2016, 6, 25487.	3.3	125
7	Enhanced Physiochemical and Mechanical Performance of Chitosan-Grafted Graphene Oxide for Superior Osteoinductivity. <i>Advanced Functional Materials</i> , 2016, 26, 1085-1097.	14.9	118
8	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. <i>Gut</i> , 2016, 65, 313-320.	12.1	112
9	Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. <i>Journal of Hepatology</i> , 2020, 72, 736-745.	3.7	109
10	The role of miR-135-modified adipose-derived mesenchymal stem cells in bone regeneration. <i>Biomaterials</i> , 2016, 75, 279-294.	11.4	92
11	Effects of miR-146a on the osteogenesis of adipose-derived mesenchymal stem cells and bone regeneration. <i>Scientific Reports</i> , 2017, 7, 42840.	3.3	87
12	Sofosbuvir+velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 127-134.	8.1	83
13	Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHES2101): A multicenter study. <i>Journal of Hepatology</i> , 2021, 75, 439-441.	3.7	82
14	HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-10.	1.4	82
15	A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2014, 59, 1714-1723.	5.8	79
16	Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. <i>Microbes and Infection</i> , 2009, 11, 515-523.	1.9	78
17	Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation. <i>Journal of Hepatology</i> , 2015, 63, 50-59.	3.7	76
18	Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucleos(t)ide Analogue Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 719-727.e7.	4.4	72

#	ARTICLE	IF	CITATIONS
19	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 271-280.	0.4	72
20	Effects of miR-31 on the osteogenesis of human mesenchymal stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 446, 98-104.	2.1	70
21	PEGylated poly(glycerol sebacate)-modified calcium phosphate scaffolds with desirable mechanical behavior and enhanced osteogenic capacity. <i>Acta Biomaterialia</i> , 2016, 44, 110-124.	8.3	67
22	Structure–function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6). <i>Virology</i> , 2011, 420, 10-19.	2.4	58
23	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	4.0	58
24	Characterization of human ethmoid sinus mucosa derived mesenchymal stem cells (hESMSCs) and the application of hESMSCs cell sheets in bone regeneration. <i>Biomaterials</i> , 2015, 66, 67-82.	11.4	56
25	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 227-252.	1.5	55
26	MBG-Modified β -TCP Scaffold Promotes Mesenchymal Stem Cells Adhesion and Osteogenic Differentiation via a FAK/MAPK Signaling Pathway. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 30283-30296.	8.0	52
27	Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1929-1936.e1.	4.4	51
28	Combining Hepatitis B Virus RNA and Hepatitis B Core–Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen–Positive Patients With Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2020, 222, 611-618.	4.0	50
29	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 538-544.	8.1	49
30	Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. <i>Journal of Hepatology</i> , 2015, 63, 148-155.	3.7	48
31	Enhanced autophagy contributes to protective effects of IL-22 against acetaminophen-induced liver injury. <i>Theranostics</i> , 2018, 8, 4170-4180.	10.0	48
32	Effects of let-7b and TLX on the proliferation and differentiation of retinal progenitor cells in vitro. <i>Scientific Reports</i> , 2014, 4, 6671.	3.3	47
33	Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). <i>Journal of Infectious Diseases</i> , 2017, 215, 1085-1093.	4.0	46
34	Constraint-induced aphasia therapy in post-stroke aphasia rehabilitation: A systematic review and meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2017, 12, e0183349.	2.5	40
35	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	4.0	40
36	M2 microglia-derived extracellular vesicles promote white matter repair and functional recovery via miR-23a-5p after cerebral ischemia in mice. <i>Theranostics</i> , 2022, 12, 3553-3573.	10.0	40

#	ARTICLE	IF	CITATIONS
37	Evaluation of Functional Correlation of Task-Specific Muscle Synergies with Motor Performance in Patients Poststroke. <i>Frontiers in Neurology</i> , 2017, 8, 337.	2.4	38
38	Atg7 Knockdown Augments Concanavalin A-Induced Acute Hepatitis through an ROS-Mediated p38/MAPK Pathway. <i>PLoS ONE</i> , 2016, 11, e0149754.	2.5	37
39	Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic <scp>HBV</scp> infection. <i>Liver International</i> , 2017, 37, 1612-1621.	3.9	37
40	miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder. <i>Journal of Hepatology</i> , 2021, 74, 8-19.	3.7	37
41	The Use of NACSELD and EASL-CLIF Classification Systems of ACLF in the Prediction of Prognosis in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2020, 115, 2026-2035.	0.4	37
42	A regulatory loop containing miR-26a, GSK3 β and C/EBP β regulates the osteogenesis of human adipose-derived mesenchymal stem cells. <i>Scientific Reports</i> , 2015, 5, 15280.	3.3	36
43	Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. <i>Journal of Hepatology</i> , 2016, 65, 674-682.	3.7	36
44	Modulation of bile acid profile by gut microbiota in chronic hepatitis B. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2573-2581.	3.6	36
45	Electrospun silk fibroin/poly(lactide-co- ϵ -caprolactone) nanofibrous scaffolds for bone regeneration. <i>International Journal of Nanomedicine</i> , 2016, 11, 1483.	6.7	35
46	Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. <i>PLoS ONE</i> , 2016, 11, e0155934.	2.5	34
47	Long-Term Bone Regeneration Enabled by a Polyhedral Oligomeric Silsesquioxane (POSS)-Enhanced Biodegradable Hydrogel. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 4612-4623.	5.2	33
48	A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1860-1867.	2.8	32
49	Effects of transcranial direct current stimulation with virtual reality on upper limb function in patients with ischemic stroke: a randomized controlled trial. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2020, 17, 73.	4.6	31
50	The influence of frame alignment with dose compensation on the quality of single particle reconstructions. <i>Journal of Structural Biology</i> , 2015, 192, 196-203.	2.8	30
51	The 2.8Å... Electron Microscopy Structure of Adeno-Associated Virus-DJ Bound by a Heparinoid Pentasaccharide. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 5, 1-12.	4.1	30
52	Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: Single-center prospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 1323-1329.	0.9	30
53	The Effectiveness of Acupuncture for Osteoporosis: A Systematic Review and Meta-Analysis. <i>The American Journal of Chinese Medicine</i> , 2018, 46, 489-513.	3.8	29
54	Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. <i>Hepatology International</i> , 2019, 13, 573-586.	4.2	29

#	ARTICLE	IF	CITATIONS
55	A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 124.	2.4	28
56	Rapamycin Increases Collateral Circulation in Rodent Brain after Focal Ischemia as detected by Multiple Modality Dynamic Imaging. <i>Theranostics</i> , 2019, 9, 4923-4934.	10.0	28
57	Real-world treatment patterns and clinical outcomes of HCV treatment-naïve patients in China: an interim analysis from the CCgenos study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 244-252.	2.8	27
58	PKC412 normalizes mutation-related keratin filament disruption and hepatic injury in mice by promoting keratin-myosin binding. <i>Hepatology</i> , 2015, 62, 1858-1869.	7.3	26
59	Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. <i>Hepatology International</i> , 2020, 14, 212-224.	4.2	26
60	Transcranial Focused Ultrasound Stimulation Improves Neurorehabilitation after Middle Cerebral Artery Occlusion in Mice. , 2021, 12, 50.		26
61	MicroRNA-224 Induces G1/S Checkpoint Release in Liver Cancer. <i>Journal of Clinical Medicine</i> , 2015, 4, 1713-1728.	2.4	25
62	Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway. <i>Cell Death and Disease</i> , 2018, 9, 590.	6.3	25
63	Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1085-1094.	3.1	24
64	Letter to the editor: Exacerbation of autoimmune hepatitis after COVID-19 vaccination. <i>Hepatology</i> , 2022, 75, 757-759.	7.3	24
65	Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 3057-3069.	2.8	23
66	Genetic variations of NTCP are associated with susceptibility to HBV infection and related hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 105407-105424.	1.8	23
67	Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure. <i>Scientific Reports</i> , 2015, 5, 14240.	3.3	22
68	Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00323.	2.5	22
69	Combined effect of repetitive transcranial magnetic stimulation and physical exercise on cortical plasticity. <i>Neural Regeneration Research</i> , 2020, 15, 1986.	3.0	22
70	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	5.8	21
71	Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>PLoS ONE</i> , 2015, 10, e0144425.	2.5	20
72	Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 448-456.	3.7	20

#	ARTICLE	IF	CITATIONS
73	Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBsAg-positive chronic hepatitis B infection: ARES long-term follow-up. <i>Journal of Viral Hepatitis</i> , 2019, 26, 109-117.	2.0	20
74	Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. <i>Advances in Therapy</i> , 2015, 32, 727-741.	2.9	19
75	Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. <i>Hepatology International</i> , 2018, 12, 126-132.	4.2	19
76	Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2018, 48, E213-E221.	3.4	19
77	Development of human-machine interface for teleoperation of a mobile manipulator. <i>International Journal of Control, Automation and Systems</i> , 2012, 10, 1225-1231.	2.7	18
78	Persistently elevated circulating Th22 reversely correlates with prognosis in HBV-related acute-on-chronic liver failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 677-686.	2.8	18
79	Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. <i>Hepatology International</i> , 2019, 13, 260-269.	4.2	18
80	A High Percentage of Patients Recovered From COVID-19 but Discharged With Abnormal Liver Function Tests. <i>Frontiers in Physiology</i> , 2021, 12, 642922.	2.8	18
81	Repetitive Transcranial Magnetic Stimulation on the Affected Hemisphere Enhances Hand Functional Recovery in Subacute Adult Stroke Patients: A Randomized Trial. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 636184.	3.4	18
82	Crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 6. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2008, 64, 1074-1078.	0.7	17
83	Correlation between circulating miR-122 and prognosis of chronic HBV-related liver failure. <i>Journal of Digestive Diseases</i> , 2016, 17, 334-339.	1.5	17
84	Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1168-1176.	2.8	17
85	Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 61-69.	3.1	17
86	HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. <i>Antiviral Research</i> , 2018, 158, 178-184.	4.1	17
87	The impact of HBV flare on the outcome of HBV-related decompensated cirrhosis patients with bacterial infection. <i>Liver International</i> , 2019, 39, 1943-1953.	3.9	17
88	Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. <i>Frontiers in Microbiology</i> , 2019, 10, 535.	3.5	17
89	High-Throughput Screening for Drugs that Modulate Intermediate Filament Proteins. <i>Methods in Enzymology</i> , 2016, 568, 163-185.	1.0	16
90	The Effects of Combined Low Frequency Repetitive Transcranial Magnetic Stimulation and Motor Imagery on Upper Extremity Motor Recovery Following Stroke. <i>Frontiers in Neurology</i> , 2019, 10, 96.	2.4	16

#	ARTICLE	IF	CITATIONS
91	Electron microscopy analysis of a disaccharide analog complex reveals receptor interactions of adeno-associated virus. <i>Journal of Structural Biology</i> , 2013, 184, 129-135.	2.8	15
92	Antimicrobial Resistance and Molecular Epidemiology of Uropathogenic <i>Escherichia coli</i> Isolated From Female Patients in Shanghai, China. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 653983.	3.9	15
93	Establishing a metabolomic model for the prognosis of hepatitis B virus-induced acute-on-chronic liver failure treated with different liver support systems. <i>Metabolomics</i> , 2011, 7, 400-412.	3.0	14
94	Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: A randomized trial. <i>Journal of Clinical Virology</i> , 2014, 61, 509-516.	3.1	14
95	Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. <i>Scientific Reports</i> , 2015, 5, 17123.	3.3	14
96	Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1989-1996.	3.3	14
97	Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 2001-2009.	2.7	14
98	Serotype Distribution, Antimicrobial Susceptibility, and Multilocus Sequencing Type (MLST) of <i>Streptococcus pneumoniae</i> From Adults of Three Hospitals in Shanghai, China. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 407.	3.9	14
99	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 71-81.	4.2	14
100	Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. <i>Scientific Reports</i> , 2016, 6, 37498.	3.3	13
101	Long Non-coding RNA NEAT1 Alleviates Acute-on-Chronic Liver Failure Through Blocking TRAF6 Mediated Inflammatory Response. <i>Frontiers in Physiology</i> , 2019, 10, 1503.	2.8	13
102	Development and Feasibility Assessment of a Rotational Orthosis for Walking with Arm Swing. <i>Frontiers in Neuroscience</i> , 2017, 11, 32.	2.8	12
103	Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients. <i>Hepatology Research</i> , 2018, 48, 134-143.	3.4	12
104	Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. <i>Journal of Medical Virology</i> , 2019, 91, 1313-1318.	5.0	12
105	Dynamics of Hepatitis E Virus (HEV) Antibodies and Development of a Multifactorial Model To Improve the Diagnosis of HEV Infection in Resource-Limited Settings. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	12
106	Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-8.	1.4	12
107	Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China. <i>World Journal of Hepatology</i> , 2019, 11, 421-441.	2.0	12
108	Respiratory Muscle Training Reduces Respiratory Complications and Improves Swallowing Function After Stroke: A Systematic Review and Meta-Analysis. <i>Archives of Physical Medicine and Rehabilitation</i> , 2022, 103, 1179-1191.	0.9	12

#	ARTICLE	IF	CITATIONS
109	SUMO-specific protease 3 is a key regulator for hepatic lipid metabolism in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 37351.	3.3	11
110	Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. <i>Journal of Digestive Diseases</i> , 2020, 21, 519-525.	1.5	11
111	Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1967-1973.	4.0	11
112	External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy. <i>Frontiers in Medicine</i> , 2021, 8, 677920.	2.6	11
113	Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-8.	1.4	11
114	COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status. <i>Infectious Diseases of Poverty</i> , 2022, 11, 56.	3.7	11
115	A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. <i>Value in Health Regional Issues</i> , 2013, 2, 48-56.	1.2	10
116	Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening. <i>Cell and Bioscience</i> , 2015, 5, 66.	4.8	10
117	Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China. <i>Journal of Medical Virology</i> , 2017, 89, 1973-1980.	5.0	10
118	Automated functional electrical stimulation training system for upper-limb function recovery in poststroke patients. <i>Medical Engineering and Physics</i> , 2020, 84, 174-183.	1.7	10
119	Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin-Tazobactam and Ceftolozane-Tazobactam in Tigecycline-Non-Susceptible <i>Klebsiella pneumoniae</i> . <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4309-4319.	2.7	10
120	Serum hepatocyte apoptosis biomarker predicts the presence of significant histological lesion in chronic hepatitis B virus infection. <i>Digestive and Liver Disease</i> , 2016, 48, 1463-1470.	0.9	9
121	Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury. <i>Frontiers in Immunology</i> , 2022, 13, 772368.	4.8	9
122	Simeprevir plus peginterferon/ribavirin for HCV genotype 1 infected treatment-naïve patients in China and South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 912-920.	2.8	8
123	Serum keratin 18 fragments as cell death biomarker in association with disease progression and prognosis in hepatitis B virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 835-845.	2.0	8
124	Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis C. <i>Current Medical Research and Opinion</i> , 2019, 35, 847-857.	1.9	8
125	Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase. <i>Antiviral Research</i> , 2020, 184, 104953.	4.1	8
126	Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2019, X, 1-7.	1.4	8

#	ARTICLE	IF	CITATIONS
127	A pilot study of synergy-based FES for upper-extremity poststroke rehabilitation. <i>Neuroscience Letters</i> , 2022, 780, 136621.	2.1	8
128	Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial. <i>Journal of Digestive Diseases</i> , 2018, 19, 144-154.	1.5	7
129	Variable High-Frequency Deep Brain Stimulation of the Subthalamic Nucleus for Speech Disorders in Parkinson's Disease: A Case Report. <i>Frontiers in Neurology</i> , 2019, 10, 379.	2.4	7
130	Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome. <i>Frontiers in Physiology</i> , 2020, 11, 526.	2.8	7
131	3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	7
132	Neural computational modeling reveals a major role of corticospinal gating of central oscillations in the generation of essential tremor. <i>Neural Regeneration Research</i> , 2017, 12, 2035.	3.0	7
133	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2022, 16, 48-58.	4.2	7
134	Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial. <i>Liver International</i> , 2022, 42, 1803-1813.	3.9	7
135	Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. <i>Antiviral Research</i> , 2019, 171, 104612.	4.1	6
136	Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China. <i>BMC Gastroenterology</i> , 2019, 19, 65.	2.0	6
137	Laboratory-based Surveillance and Clinical Profile of Sporadic HEV Infection in Shanghai, China. <i>Virologica Sinica</i> , 2021, 36, 644-654.	3.0	6
138	Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. <i>World Journal of Gastroenterology</i> , 2018, 24, 1361-1372.	3.3	6
139	Bacterial infection triggers and complicates acute-on-chronic liver failure in patients with hepatitis B virus-decompensated cirrhosis: A retrospective cohort study. <i>World Journal of Gastroenterology</i> , 2020, 26, 645-656.	3.3	6
140	Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population. <i>Infection, Genetics and Evolution</i> , 2015, 31, 161-168.	2.3	5
141	Sentinel surveillance strategies for early detection of coronavirus disease in fever clinics: experience from China. <i>Epidemiology and Infection</i> , 2020, 148, e205.	2.1	5
142	Autoimmune liver disease-associated serologic profiling in Chinese patients with acute hepatitis E virus infection. <i>Immunologic Research</i> , 2021, 69, 81-89.	2.9	5
143	Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 10, 128-133.	1.4	5
144	Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 733348.	3.9	5

#	ARTICLE	IF	CITATIONS
145	Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2023, 23, 397-409.	3.6	5
146	Activity identification of chimeric anti-caspase-3 mRNA hammerhead ribozyme in vitro and in vivo. <i>Science in China Series C: Life Sciences</i> , 2001, 44, 618-627.	1.3	4
147	Correlation between hepatic human males absent on the first (hMOF) and viral persistence in chronic hepatitis B patients. <i>Cell and Bioscience</i> , 2018, 8, 14.	4.8	4
148	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 874-885.e4.	4.4	4
149	A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-9.	1.4	4
150	Real-World Clinical Outcomes among Individuals with Chronic HCV Infection in China: CCgenos Study. <i>Antiviral Therapy</i> , 2019, 24, 473-483.	1.0	4
151	Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance. <i>Antiviral Research</i> , 2022, 197, 105224.	4.1	4
152	Genetic Variations of ALDH (rs671) Are Associated With the Persistence of HBV Infection Among the Chinese Han Population. <i>Frontiers in Medicine</i> , 2022, 9, 811639.	2.6	4
153	A framework for quantifying the effects of transcranial magnetic stimulation on motor recovery from hemiparesis: corticomuscular network. <i>Journal of Neural Engineering</i> , 2022, 19, 026053.	3.5	4
154	PP2 protects from keratin mutation-associated liver injury and filament disruption via SRC kinase inhibition in male but not female mice. <i>Hepatology</i> , 2023, 77, 144-158.	7.3	4
155	A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients. <i>Scientific Reports</i> , 2016, 6, 28779.	3.3	3
156	Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy. <i>Oncotarget</i> , 2016, 7, 58553-58562.	1.8	3
157	Peginterferon and Entecavir Combination Therapy Improves Outcome of Non-“Early Response Hepatitis B e Antigen-“Positive Patients. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa462.	0.9	3
158	The development of an exoskeleton robot for co-manipulation of human upper limb movement. , 2012, , .		2
159	IPS-1 polymorphisms in regulating interferon response in HBV infection. <i>BioScience Trends</i> , 2019, 13, 130-135.	3.4	2
160	Unsatisfying antiviral therapeutic effect in patients with mother-to-child transmitted chronic hepatitis B virus infection. <i>Chinese Medical Journal</i> , 2019, 132, 2647-2656.	2.3	2
161	A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir) Tj ETQq1 1 0.784314 rgBT /Overl... 2019, 98, e16778.	1.0	2
162	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , 2020, 15, e0230893.	2.5	2

#	ARTICLE	IF	CITATIONS
163	A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China. <i>Antiviral Research</i> , 2021, 194, 105163.	4.1	2
164	Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure. <i>Gut and Liver</i> , 2022, 16, 456-464.	2.9	2
165	ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHES2108): an international, multicenter cohort study. <i>Hepatology International</i> , 2022, 16, 1105-1115.	4.2	2
166	Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	2.8	1
167	Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data. <i>Gut</i> , 2022, 71, 445-446.	12.1	1
168	Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211027.	2.5	1
169	240-week Entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C. <i>Journal of Viral Hepatitis</i> , 0, , .	2.0	1
170	Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections. <i>Frontiers of Medicine</i> , 2021, 15, 644-648.	3.4	0
171	Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. <i>World Journal of Clinical Cases</i> , 2021, 9, 4690-4699.	0.8	0
172	Long Non-coding RNA and mRNA Expression Change in Spinal Dorsal Horn After Exercise in Neuropathic Pain Rats. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 865310.	2.9	0
173	qHBsAg for the Identification of Liver Histological Abnormalities in HBeAg-Negative Chronic Hepatitis B Patients with Normal and Mildly Elevated ALT Levels. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-7.	1.9	0